AU623347B2 - Thrombolytic agent - Google Patents

Thrombolytic agent Download PDF

Info

Publication number
AU623347B2
AU623347B2 AU22400/88A AU2240088A AU623347B2 AU 623347 B2 AU623347 B2 AU 623347B2 AU 22400/88 A AU22400/88 A AU 22400/88A AU 2240088 A AU2240088 A AU 2240088A AU 623347 B2 AU623347 B2 AU 623347B2
Authority
AU
Australia
Prior art keywords
pro
lys
plasminogen
dosage
pig
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU22400/88A
Other languages
English (en)
Other versions
AU2240088A (en
Inventor
Vincent John Ellis
Vijay Vir Kakkar
Michael Finbarr Scully
Yoichi Watahiki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trigen Ltd
Original Assignee
Thrombosis Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombosis Research Institute filed Critical Thrombosis Research Institute
Publication of AU2240088A publication Critical patent/AU2240088A/en
Assigned to THROMBOSIS RESEARCH INSTITUTE reassignment THROMBOSIS RESEARCH INSTITUTE Alteration of Name(s) of Applicant(s) under S113 Assignors: THROMBOSIS RESEARCH TRUST
Application granted granted Critical
Publication of AU623347B2 publication Critical patent/AU623347B2/en
Assigned to ELLERMAN PHARMACEUTICALS LIMITED reassignment ELLERMAN PHARMACEUTICALS LIMITED Alteration of Name(s) in Register under S187 Assignors: THROMBOSIS RESEARCH INSTITUTE
Assigned to TRIGEN LIMITED reassignment TRIGEN LIMITED Request to Amend Deed and Register Assignors: ELLERMAN PHARMACEUTICALS LIMITED
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU22400/88A 1987-09-18 1988-09-19 Thrombolytic agent Ceased AU623347B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878721951A GB8721951D0 (en) 1987-09-18 1987-09-18 Organic compounds
GB8721951 1987-09-18

Publications (2)

Publication Number Publication Date
AU2240088A AU2240088A (en) 1989-03-23
AU623347B2 true AU623347B2 (en) 1992-05-14

Family

ID=10623981

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22400/88A Ceased AU623347B2 (en) 1987-09-18 1988-09-19 Thrombolytic agent

Country Status (11)

Country Link
EP (1) EP0307847B1 (OSRAM)
JP (1) JP2820699B2 (OSRAM)
AT (1) ATE82860T1 (OSRAM)
AU (1) AU623347B2 (OSRAM)
CA (1) CA1337046C (OSRAM)
DE (1) DE3876348T2 (OSRAM)
DK (1) DK518788A (OSRAM)
ES (1) ES2053658T3 (OSRAM)
GB (1) GB8721951D0 (OSRAM)
GR (1) GR3007194T3 (OSRAM)
NZ (1) NZ226217A (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
AT402263B (de) * 1991-06-20 1997-03-25 Immuno Ag Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
WO1994001128A1 (en) * 1992-07-01 1994-01-20 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
DE4411143C2 (de) * 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
DK3391902T5 (da) * 2015-12-18 2024-09-23 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
CN106890318A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病性心脏病的新方法
JP7213553B2 (ja) 2016-12-15 2023-01-27 タレンゲン インターナショナル リミテッド 肺の繊維化を予防及び治療するための方法
JP7175270B2 (ja) 2016-12-15 2022-11-18 タレンゲン インターナショナル リミテッド グルカゴン、インスリンを正常なバランスに戻らせる方法
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
TW202123963A (zh) 2016-12-15 2021-07-01 大陸商深圳瑞健生命科學研究院有限公司 一種治療冠狀動脈粥樣硬化及其併發症的方法
WO2018107707A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种改善心脏病变的方法
JP7335609B2 (ja) 2017-06-19 2023-08-30 タレンゲン インターナショナル リミテッド Ｇｌｐ－１／ｇｌｐ－１ｒを調節制御する方法および薬剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504921A1 (fr) * 1981-04-30 1982-11-05 Choay Sa Medicament nouveau constitue par un complexe aprotinine-plasmine et procede de preparation de ce nouveau complexe
IL80166A0 (en) * 1985-10-01 1986-12-31 American Home Prod Method of enhancing t-pa and scu-pa production

Also Published As

Publication number Publication date
DE3876348T2 (de) 1993-06-09
GB8721951D0 (en) 1987-10-28
DK518788D0 (da) 1988-09-16
NZ226217A (en) 1991-07-26
EP0307847A3 (en) 1990-03-07
ATE82860T1 (de) 1992-12-15
JP2820699B2 (ja) 1998-11-05
DE3876348D1 (en) 1993-01-14
EP0307847B1 (en) 1992-12-02
DK518788A (da) 1989-03-19
AU2240088A (en) 1989-03-23
JPH0283335A (ja) 1990-03-23
GR3007194T3 (OSRAM) 1993-07-30
EP0307847A2 (en) 1989-03-22
ES2053658T3 (es) 1994-08-01
CA1337046C (en) 1995-09-19

Similar Documents

Publication Publication Date Title
AU623347B2 (en) Thrombolytic agent
EP0751785B2 (en) Combinations of thrombolytically active proteins and anticoagulants, and uses thereof
Tamao et al. Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo
JPS6236332A (ja) 医薬投与単位
Smith et al. Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis
US6969515B2 (en) Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US5055295A (en) Lysis of fibrin blood clots with urokinase and pro-urokinase
US5279824A (en) Pharmaceutical formulation containing heparin and endo-beta-glucuronidase, useful for the treatment of thrombosis
US4999194A (en) Two-chain urokinase plasminogen activators for treatment of thrombotic disease
US6759042B2 (en) Use of cross-linked, covalently bound urokinase plasminogen activator (scuPA)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent
Credo et al. Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase
AU632482B2 (en) Heparin-containing formulations
Gulba et al. Potentiative effect of heparin in thrombolytic therapy of evolving myocardial infarction with natural pro-urokinase
CA1303987C (en) Pharmaceutical composition having thrombolytic activity
EP0381640B1 (en) New thrombolytic compositions
EP0352897B1 (en) Tpa-containing medicaments
ZA200102722B (en) Method of treating heparin-induced thrombocytopenia.
US5174994A (en) Pharmaceutical composition having thrombolytic activity
KR960002738B1 (ko) 유로키나아제를 함유하는 혈정용해제
Tebbe et al. Thrombolytic therapy of acute myocardial infarction with saruplase, a single-chain urokinase-type plasminogen activator (scu-PA) from recombinant bacteria
Matthias Mode of Action and Characteristics of Some Coagulation-Active Drugs and Their Dosage
WO2018232305A1 (en) Methods and compositions for thrombolysis
JPS6259221A (ja) 組織プラスミノ−ゲン活性化因子含有組成物
JPH049334A (ja) 線溶活性増強剤

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired